A mid-stage trial of BPL‑003 nasal spray shows promising results for treatment-resistant depression, igniting biotech ...

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

A nasal spray for treatment-resistant depression has delivered strong clinical results and rekindled investor hopes.

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression. Spravato ...

Jan. 27, 2025 – After years of limited options, people with hard-to-treat depression finally have a new standalone treatment. The FDA’s latest approval of the nasal spray Spravato (esketamine ...

Spravato nasal spray has been FDA approved to treat depression. Here's how the esketamine spray works, esketamine vs. ketamine, and potential risks.

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called ...

BPL-003 showed “robust” efficacy data in treatment-resistant depression, according to analysts from Jefferies, who noted that ...

The Food and Drug Administration has approved a new nasal spray for the treatment of severe depression. On Tuesday, the government agency announced Spravato nasal spray, also known as esketamine ...

ALBUQUERQUE, N.M. — The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression. The drug, SPRAVATO, is made by Johnson & Johnson and was first ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression.